Experimental and clinical study on inhibition and reversion of Liver fibrosis with integrated Chinese and western medicine

Wang Baoen; Wang Tailing; Jia Jidong; Ma Hong; Duan Zhongping; Li Xinmin; Li Jia; Wang Aimin; Qian Linxue

doi:10.1007/BF02934179

Your Location：

Home >

Browse articles >

Experimental and clinical study on inhibition and reversion of Liver fibrosis with integrated Chinese and western medicine

Updated：2021-08-27

- Experimental and clinical study on inhibition and reversion of Liver fibrosis with integrated Chinese and western medicine
- Chinese Journal of Integrative Medicine Vol. 5, Issue 1, Pages: 6-11(1999)
- Affiliations：
  
  Beijing Friendship Hospital, Capital University of Medical Sciences,Beijing
- Author bio：
- Funds：
- DOI：10.1007/BF02934179
  CLC：
- Published：1999，
Scan for full text
Baoen, W., Tailing, W., Jidong, J. et al. Experimental and clinical study on inhibition and reversion of Liver fibrosis with integrated Chinese and western medicine., CJIM 5, 6 (1999). https://doi.org/10.1007/BF02934179

Wang Baoen, Wang Tailing, Jia Jidong, et al. Experimental and clinical study on inhibition and reversion of Liver fibrosis with integrated Chinese and western medicine. [J]. Chinese Journal of Integrative Medicine 5(1):6-11(1999)
Baoen, W., Tailing, W., Jidong, J. et al. Experimental and clinical study on inhibition and reversion of Liver fibrosis with integrated Chinese and western medicine., CJIM 5, 6 (1999). https://doi.org/10.1007/BF02934179 DOI：

Wang Baoen, Wang Tailing, Jia Jidong, et al. Experimental and clinical study on inhibition and reversion of Liver fibrosis with integrated Chinese and western medicine. [J]. Chinese Journal of Integrative Medicine 5(1):6-11(1999) DOI： 10.1007/BF02934179.

摘要

Objective: To explore the possibility of reverting HBV-related hepatic fibrosis and cirrhosis with traditional Chinese medicine (TCM).Methods: A herbal recipe (861)

comprising of 10 herbs includingSalvia miltiorrhiza

Astragalus membranaceus andSpatholobus saberectus were used as the antifibrotic agents. Three controlled clinical trials of treating HBV-related fibrosis and early cirrhosis were carried out. A total of 107 patients were assessed clinically and pathologically with double liver biopsies before and after treatment by means of modified Scheuer and Chevallier scoring system. Rat model of hepatic fibrosis induced by CC14 and human albumin immune injury

culture of separated hepatic stellate cells (HSC) were established. Total collagen content of the liver was determined by detection of hydroxyproline

amount of type I

III

IV collagens by histoimmunochemistry

quantitative measurement of mRNA for collagen I

III

transforming growth factor-β (TGF-(3)

matrix metalloproteinase (MMP1)

MMP2

tissue inhibitor of metalloproteinase (TIMP) in liver tissue by dot blot hybridization. Serum and liver tissue collagenase activity was detected by method of Rajabi M and Emonard H. Histopathological study of liver specimen was done with H. E.

Masson and sirius red stain as well as histoimmunochemistry.Results: (1) In HBV-related patients

after six months treatment with 861

the reversion rate was as high as 78% in S2

82% in S3 (precirrhotic stage) and 75% in S4 (cirrhosis). These results correspond well with that obtained in animal experiment. (2) Total and type I

III

V collagen content in animal model liver were significantly reduced in amount after 861 treatment

whereas quantitation of mRNA for collagen I

III

V and TGF-β were also markedly suppressed either in liver tissue or cultured HSC

suggesting the suppression by 861 on fibrogenesis. At the same time

serum and liver tissue collagenase activity (latent and active) were enhanced significantly by administration of 861

while mRNA for MMP1 (interstitial collagenase) in cultured HSC and collagenase activity in the supernatant of the HSC culture were both increased

and meantime

mRNA for TIMP1 was significantly suppressed in quantity

indicating the enhancement of excessive extracellular matrix (ECM) degradation after 861 treatment.Conclusions: (1) Contrary to the conventional concept

the liver fibrosis and early cirrhosis due to HBV infection in man could be definitely reversed by TCM treatment of 861. This was also verified in CCI4 and immune injury models. (2) The mechanism leading to the reversal of fibrosis was due to suppression of fibrogenesis

and the concurrent enhancement of ECM degradation. In the latter

suppression of TIMP also plays an important role. (3) Both initiation by imflammation and perpetuation of the activation of HSC were suppressed by the 861.

Abstract

Objective: To explore the possibility of reverting HBV-related hepatic fibrosis and cirrhosis with traditional Chinese medicine (TCM).Methods: A herbal recipe (861)

comprising of 10 herbs includingSalvia miltiorrhiza

culture of separated hepatic stellate cells (HSC) were established. Total collagen content of the liver was determined by detection of hydroxyproline

amount of type I

III

IV collagens by histoimmunochemistry

quantitative measurement of mRNA for collagen I

III

transforming growth factor-β (TGF-(3)

matrix metalloproteinase (MMP1)

MMP2

Masson and sirius red stain as well as histoimmunochemistry.Results: (1) In HBV-related patients

after six months treatment with 861

the reversion rate was as high as 78% in S2

82% in S3 (precirrhotic stage) and 75% in S4 (cirrhosis). These results correspond well with that obtained in animal experiment. (2) Total and type I

III

V collagen content in animal model liver were significantly reduced in amount after 861 treatment

whereas quantitation of mRNA for collagen I

III

V and TGF-β were also markedly suppressed either in liver tissue or cultured HSC

suggesting the suppression by 861 on fibrogenesis. At the same time

serum and liver tissue collagenase activity (latent and active) were enhanced significantly by administration of 861

while mRNA for MMP1 (interstitial collagenase) in cultured HSC and collagenase activity in the supernatant of the HSC culture were both increased

and meantime

mRNA for TIMP1 was significantly suppressed in quantity

indicating the enhancement of excessive extracellular matrix (ECM) degradation after 861 treatment.Conclusions: (1) Contrary to the conventional concept

and the concurrent enhancement of ECM degradation. In the latter

suppression of TIMP also plays an important role. (3) Both initiation by imflammation and perpetuation of the activation of HSC were suppressed by the 861.

关键词

Liver Fibrosisliver cirrhosisreversal treatmentTraditional Chinese Medicine Treatment

Keywords

Liver Fibrosisliver cirrhosisreversal treatmentTraditional Chinese Medicine Treatment

references

Greenwel P, Geerts A, Ogata I, et al. Liver fibrosis. In: Arias LM. Boyer JL, Fausto N. et al. editors. The liver: biology and pathobiology. 3rd ed. New York: Raven Presss, 1994:1367–1381.

Sherlock S, Dooley J. Diseases of the liver and biliary system. 9th. ed. Oxford: Blackwell Sci Pub, 1997:351.

Scott L. Friedman. Hepatic fibrosis. In: Schiff ER, Sorrell MF, Maddrey WC, eds. Diseases of the Liver. 8th. ed. New York: Lippincott-Raven Pub, 1999:371.

1990; 21(4): 23–25.

1997; 5(2): 77.

1998; (2): 148.

861 1999; 7(1): 36.

1989; 69: 503–505.

1993; 1(2): 69–72.

1983; 6: 133.

Friedman SL, Roll FJ. Isolation and culture of hepatic lipocyte, Kupffer cells and sinusoidal endothelial cell by density gradient centrifugation with stractan. Anal Biochem. 1987; 161: 207–208.

Emonard H, Grimaud JA. Active and latent collagenase activity during reversal of hepatic fibrosis in murine schistosomiasis. Hepatology 1989; 10:77.

Rajabi M, Dean DD, Woessner JF. High levels of serum collagenase in premature labor-A potential biochemical marker. Obstet Gyncol 1987; 69:179.

1995 1995; 34: 788–791.

Chevallier M, Guerret S, Chossegros P, et al. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology 1994; 20:349.

Sun M, Wang BE, et al. Two rat models of hepatic fibrosis: A morphology and molecular comparison. Lab. Invest 1990; 63: 467–475.

861 I, JV TGF-β mRNA 1996; 4(4): 214.

861 1996; 4(3): 142.

Ma H, Wang BE, Ma XM. The effect of compound 861 on hepatic stellate cell (HSC) proliferation, collagen synthesis and degradation in vitro. J Gastroenterol Hepatol 1997; 12(suppl): S97.

1997; 4(2): 56.

861 1998; 3(3): 172.

FULL TEXT LINK

More>

Views

344

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Xiayuxue Decoction (下瘀血汤) attenuates hepatic stellate cell activation and sinusoidal endothelium defenestration in CCl4-induced fibrotic liver of mice

Pay attention to the study on active antiliver fibrosis components of Chinese herbal medicine

Effect of oxymatrine on hepatic gene expression profile in experimental liver fibrosis of rats

Fuzheng Huayu Capsule (扶正化瘀胶囊) in the treatment of liver fibrosis: Clinical evidence and mechanism of action

Related Author

No data

Related Institution

The First Affiliated Hospital of Anhui College of Traditional Chinese Medicine

Key Laboratory of Liver and Kidney Diseases, Shanghai University of Traditional Chinese Medicine

Institute of Traditional Chinese Internal Medicine, Shanghai Municipal Education Commission, Shanghai

Institute of Liver Diseases, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine

Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Institute of Liver Diseases, Shanghai University of Chinese medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰